Heron Therapeutics Enters Material Definitive Agreement

Ticker: HRTX · Form: 8-K · Filed: Feb 20, 2025 · CIK: 818033

Sentiment: neutral

Topics: material-agreement, corporate-news

Related Tickers: HRTX

TL;DR

HRTX signed a big deal, details to come.

AI Summary

Heron Therapeutics, Inc. (HRTX) announced on February 13, 2025, that it entered into a material definitive agreement. The company, formerly known as AP Pharma Inc. and Advanced Polymer Systems Inc., is headquartered in San Diego, California.

Why It Matters

This filing indicates a significant new contract or partnership for Heron Therapeutics, which could impact its future revenue and strategic direction.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the specifics of which are not yet detailed in this initial filing.

Key Numbers

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Heron Therapeutics?

The filing does not specify the details of the material definitive agreement, only that one was entered into on February 13, 2025.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on February 13, 2025.

What is Heron Therapeutics' principal executive office address?

Heron Therapeutics' principal executive offices are located at 100 Regency Forest Drive, Suite 300, Cary, NC 27518.

What were Heron Therapeutics' former company names?

Heron Therapeutics was formerly known as AP PHARMA INC /DE/ and ADVANCED POLYMER SYSTEMS INC /DE/.

What is Heron Therapeutics' SEC File Number?

Heron Therapeutics' SEC File Number is 001-33221.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on February 20, 2025 regarding HERON THERAPEUTICS, INC. /DE/ (HRTX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing